As part of her MPH Practicum summer project, Trinity Perkins is serving in a special capacity as a health policy and educational legislative intern for Senator Sheldon Whitehouse.
A Health Equity Scholar, and a member of a Texas family who has long been politically engaged, Perkins is passionate about policy, especially as it relates to education and public health.
Her role in the Providence office of Senator Sheldon Whitehouse (D-RI) involves analyzing bills that come up in the Senate, and sometimes the House, to determine if they align with Whitehouse’s mission and administration.
Perkins participates in legislative meetings and occasionally joins Senate hearings remotely. Following these sessions, she discusses her observations with other legislative correspondents and makes recommendations. For instance, Perkins might suggest that the Senator co-sponsor bills based on past actions and current relevance. This involvement ensures that she contributes to both retrospective and prospective legislative analysis.
While working on policy and Washington, D.C. action items, Perkins also serves as a point person for Rhode Island constituents. This dual role—serving as a bridge between the Providence and D.C. offices—gives her insight into the discussions taking place in the nation’s capital while evaluating the needs of R.I. residents.
We spoke with Trinity about her MPH Practicum experience this summer.
Is there a particular piece of legislation that caught your attention?
I have been closely tracking updates on the Certified Community Behavioral Health Center (CCBHC) Program. One of the reasons I was drawn to work for Senator Whitehouse is his unwavering commitment to mental health issues. With a bachelor's degree in psychology, I bring a unique perspective that combines my educational background with a keen understanding of the legislative aspects of this program.
I am particularly excited about the Senator’s courageous stance against big pharmaceutical companies. Currently, Senator Whitehouse is actively urging pharmaceutical companies to lower prescription medication costs. This will remain a key issue we work diligently on.